Clinical trials: GnRH Antagonist
Infertility
FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety of two different subcutaneous FSH preparations (Fostimon versus Gonal-F) for controlled ovarian hyperstimulation in a GnRH-antagonist…
- Trial name
- FAST (NCT01969201)
- Testing
- Urofollitrophin, Follitrophin alpha
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 710 people
- Sponsor
- IBSA Institut Biochimique SA
Healthy
ACY-7 Oral Administration of Acyline
We propose oral dosing of gastrointestinal permeation enhancement technology [GIPET] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four…
- Trial name
- ACY-7 (NCT00603187)
- Testing
- Acyline
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Washington
in Vitro Fertilization, Ovulation Induction
Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)
Background of the study: Milder stimulation protocols have the advantage of being less expensive and more patient-friendly. Moreover, recent evidence suggests that mild stimulation protocols lead to lower embryo aneuploidy rates…
- Trial name
- LITE (NCT00823472)
- Testing
- Mild stimulation
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Endometriosis
Cardiovascular Disease Risk in Women With Endometriosis
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
- Trial name
- NCT03746535
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy Volunteers
Letrozole Treatment in Normal and GnRH Deficient Women
This research study involves the use of the drugs Letrozole, GnRH, and NAL-GLU GnRH antagonist. Letrozole is a drug that is approved by the U.S.
- Trial name
- NCT00351416
- Testing
- Letrozole, NAL-GLU GnRH antagonist
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants.
- Trial name
- ELARIS EM-I (NCT01620528)
- Testing
- elagolix
- Volunteers
- 872 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ovarian Hyperstimulation Syndrome
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly…
- Trial name
- NCT00867659
- Testing
- Cetrotide acetate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Center for Reproductive Medicine
OHSS (Ovarian Hyperstimulation)
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles
- Trial name
- NCT00627406
- Testing
- Buserelin and Pregnyl, Pregnyl
- Where
- Denmark
- Volunteers
- 384 people
- Sponsor
- Regionshospitalet Viborg, Skive
BPH
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with…
- Trial name
- NCT00527488
- Testing
- Degarelix
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Ferring Pharmaceuticals
Infertility, Controlled Ovarian Hyperstimulation
Follicular Steroid Genesis in Controlled Ovarian Stimulation
Serum concentrations of the different hormones involved in follicular steroid genesis during a cycle of controlled ovarian stimulation with recombinant FSH or HMG will be compared in this study.
- Trial name
- ESTEFOL (NCT02738580)
- Testing
- COS with GnRH antagonists and rFSH, COS with GnRH antagonists and HP-HMG
- Where
- Spain
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Endometriosis
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in pre-menopausal women.
- Trial name
- NCT01760954
- Testing
- Elagolix
- Volunteers
- 506 people
- Sponsor
- AbbVie
Infertility
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation…
- Trial name
- MEGASET HR (NCT02554279)
- Testing
- menotropin, recombinant FSH
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate…
- Trial name
- NCT01751451
- Testing
- Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Infertility, Female
Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
The main purpose of this clinical research study is to investigate if degarelix can synchronise the growth of the egg sacs in the ovaries and if degarelix has any effect on the lining of the womb.
- Trial name
- NCT00434122
- Testing
- Degarelix mid-luteal, 2.5 mg
- Where
- 4 sites in Belgium, Czechia and 1 more
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Infertility
MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer
The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles…
- Trial name
- MEGASET (NCT00884221)
- Testing
- Highly purified menotrophin, Recombinant FSH
- Where
- 25 sites in Belgium, Czechia and 5 more
- Volunteers
- 749 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL).
- Trial name
- NCT02083185
- Testing
- Relugolix, Leuprorelin
- Where
- 23 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
In Vitro Fertilization, Intracytoplasmic Sperm Injection
Cetrotide Treatment Optimization
Rationale: In daily practice fertility treatment is increasingly patient focused and innovative medication and standardized treatment guidelines are being developed to improve patient convenience.
- Trial name
- NCT00866034
- Testing
- Cetrotide (Ovarian stimulation)
- Where
- Netherlands
- Volunteers
- 617 people, healthy volunteers welcome
- Sponsor
- Bart CJM Fauser